Fordyce Marshall's Form 4/A amendment
AmendedVera Therapeutics, Inc. (VERA) · filed Sep 13, 2022
- Accession no.
- 0001209191-22-049685
- Filed
- Sep 13, 2022
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Sep 6, 2022
This filing lists no transactions. It carries over 8 transactions from the original filing that it did not restate. Open-market sales total $721.3K.
This amendment restates part of 0001209191-22-048746 (filed Sep 6, 2022). The transactions it did not restate still count and are listed below.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Fordyce MarshallCIK 0001859453 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Carried over from the original filing
This amendment restates only part of the original filing. The original's other transactions still stand, and the trade tables on Livermore count them under this amendment.
From 0001209191-22-048746 (filed Sep 6, 2022).
Non-derivative securities (Table I)
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2022 | Class A Common Stock | MOption exerciseAcquired | +17,100 | $2.90 | +$49,590 | 198,250 | Direct | |
| Sep 1, 2022 | Class A Common Stock | SSaleDisposed | −17,100 | $21.22F2 | −$362,862 | 181,150 | Direct | |
| Sep 2, 2022 | Class A Common Stock | MOption exerciseAcquired | +7,346 | $2.90 | +$21,303.4 | 188,496 | Direct | |
| Sep 2, 2022 | Class A Common Stock | SSaleDisposed | −7,346 | $20.26F3 | −$148,829.96 | 181,150 | Direct | |
| Sep 2, 2022 | Class A Common Stock | MOption exerciseAcquired | +9,750 | $2.90 | +$28,275 | 190,900 | Direct | |
| Sep 2, 2022 | Class A Common Stock | SSaleDisposed | −9,750 | $21.50F4 | −$209,625 | 181,150 | Direct |
Derivative securities (Table II)
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 1, 2022 | Class A Common Stock | MOption exerciseDisposed | −17,100 | $0.00 | $0 | 1,073,012 | Direct | |
| Sep 2, 2022 | Class A Common Stock | MOption exerciseDisposed | −17,096 | $0.00 | $0 | 1,055,916 | Direct |
Footnotes on the original
The footnotes that the prices of these transactions refer to on the original filing.
- F2
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.69 to $21.675, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $21.00, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
- F4
The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $21.01 to $21.87, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Referenced by the price of 1 transaction in Table I.
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
1/4 of the shares subject to the option vested on December 16, 2021, and 1/48 of the shares vest monthly thereafter.
- F2
The reporting person's original Form 4 contained a typographical error on the total number of derivative securities beneficially owned following the reported transaction.